Vitrac Therapeutics
Business Services · 1-10 Employees
View Company Info for Free
Overview
Website
www.vitractherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Vitrac Therapeutics
VITRAC Therapeutics, LLC is an integrated oncology research and development company specializing in the development, management, and optimization of global pharmaceutical drug development programs. They focus on late discovery, translational research, clinical development, and post-marketing life-cycle management. Their key product, VIC-1911, is a novel, selective, orally active inhibitor of Aurora A kinase, aimed at transforming cancer treatment. The company is currently advancing the global development of VIC-1911 through innovative translational and regulatory strategies.Explore more
Popular SearchesVITRAC Therapeutics LLCSIC Code 87,873NAICS Code 54,541Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vitrac Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Vitrac Therapeutics has new funding data
Check out if Vitrac Therapeutics is spiking on competitors!
Product Launch: Get notified when Vitrac Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Vitrac Therapeutics
Earning: See what the market has to say on Vitrac Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Vitrac Therapeutics had a recent Job posting/layoffs
Vitrac Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Vitrac Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Vitrac Therapeutics
Find 2 more new buyers
Compare Similar Companies to Vitrac Therapeutics
Compare insights from companies similar to Vitrac Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Vitrac Therapeutics
<$5M
1-10
Private
-
2020
N/A
Company Profile Activity
Activity Insights
Vitrac Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vitrac Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vitrac Therapeutics.
Vitrac Therapeutics Tech Stack
A closer look at the technologies used by Vitrac Therapeutics
See more technologies
Vitrac Therapeutics News & Media
VITRAC Therapeutics Initiates a Phase 1 Clinical Trial with the Aurora Kinase A Inhibitor VIC-1911 and G12C Inhibitor Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
BOSTON--(BUSINESS WIRE)--VITRAC Therapeutics, LLC (VITRAC) initiated a Phase 1 Study of VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC). The study is being performed at Yale Cancer Center with Sarah Goldberg, MD, MPH, as Principal Investigator (PI) and Study Chair; New York University Perlmutter Cancer Center, Vamsidhar Velcheti, MD, PI; University of California Davis Comprehensive Cancer Center, Jonathan Riess,
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vitrac Therapeutics
Sign Up For FreeTo access detailed company insights
VITRAC Therapeutics, LLC is an integrated oncology research and development company specializing in the development, management, and optimization of global pharmaceutical drug development programs. They focus on late discovery, translational research, clinical development, and post-marketing life-cycle management. Their key product, VIC-1911, is a... Read More
